Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES (130/0.4)] after single-dose infusion of 6% or 10% solutions in healthy volunteers

被引:67
作者
Waitzinger, J
Bepperling, F
Pabst, G
Opitz, J
Muller, M
Baron, JF
机构
[1] LAB GmbH & Co, D-89231 Neu Ulm, Germany
[2] FRESENIUS AG, Div Pharmaceut, Bad Homburg, Germany
[3] Hop Broussais, Dept Anesthesie Reanimat, F-75674 Paris, France
关键词
D O I
10.2165/00044011-199816020-00008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To investigate the pharmacokinetic profile and tolerability of a single-dose infusion of the new hydroxyethyl starch (HES) specification, HES (130/0.4), 6% and 10% solutions in healthy volunteers. Study Design: In an open, randomised, single-dose, parallel-group study, 12 healthy volunteers (in each group) received intravenous infusions of 500ml of a new HES specification [HES (130/0.4)] of either 6% or 10% solution within 30 minutes. Results: Plasma elimination initially occurred with an a half-life of approximately 0.5 to 0.75 hour. A half-life of approximately 12 hours was reported for the terminal phase. Between 60 to 70% of the total plasma elimination was due to renal excretion. The total plasma clearances of 31.4 ml/min and 26.0 ml/min for the 6 and 10% solutions, respectively, were higher than those reported for other HES specifications. The volume of distribution in the central compartment was approximately 5.9L, which roughly corresponded to the blood volume. Single doses of 6% and 10% HES (130/0.4) were well tolerated. Conclusion: The new HES specification demonstrated favourable pharmacokinetic properties compared with other HES specifications of medium or high molecular weight. No clinically relevant plasma accumulation and related undesired effects on haemostasis are expected to occur under multiple-dose conditions.
引用
收藏
页码:151 / 160
页数:10
相关论文
共 26 条
[1]  
BARON JF, 1992, PLASMA VOLUME EXPANS, P121
[2]   RETRACTED: VOLUME REPLACEMENT WITH HYDROXYETHYL STARCH SOLUTION IN CHILDREN (Retracted article. See vol. 125, pg. 413, 2020) [J].
BOLDT, J ;
KNOTHE, C ;
SCHINDLER, E ;
HAMMERMANN, H ;
DAPPER, F ;
HEMPELMANN, G .
BRITISH JOURNAL OF ANAESTHESIA, 1993, 70 (06) :661-665
[3]   Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients [J].
Cittanova, ML ;
Leblanc, I ;
Legendre, C ;
Mouquet, C ;
Riou, B ;
Coriat, P .
LANCET, 1996, 348 (9042) :1620-1622
[4]  
CLAES Y, 1992, ANESTH ANALG, V75, P24
[5]  
Cope JT, 1997, ANN THORAC SURG, V63, P78
[6]   MECHANISMS OF POSTOPERATIVE PROLONGED PLASMA-VOLUME EXPANSION WITH LOW-MOLECULAR-WEIGHT HYDROXETHY STARCH (HES-200/0.62, 6-PERCENT) [J].
DEGREMONT, AC ;
ISMAIL, M ;
ARTHAUD, M ;
OULARE, B ;
MUNDLER, O ;
PARIS, M ;
BARON, JF .
INTENSIVE CARE MEDICINE, 1995, 21 (07) :577-583
[7]  
FERBER HP, 1985, ARZNEIMITTEL-FORSCH, V35-1, P615
[8]  
Grochenig E, 1998, PERFUSION, V11, P62
[9]  
JUNG F, 1994, CLIN HEMORHEOL, V14, P189
[10]  
KOEHLER H, 1982, Klinische Wochenschrift, V60, P293